A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pheast Therapeutics
Artios Pharma Ltd
Merck Sharp & Dohme LLC
Incyte Corporation
Esperas Pharma Inc.
Incyte Corporation